Sharp investors are usually looking for true bargains in the stock market. Finding these stocks can help give the stock portfolio a boost. Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have come into focus recently. Checking in on the stock, we can see that it has been trading near the $85.33 level. Going forward, the investment community will be closely monitoring shares looking for signs of positive momentum. Investors will often follow the current stock price relative to its 52-week high and low levels. The 52-week high is presently 177.39, and the 52-week low is sitting at 72.98. When the stock is trading near the 52-week high or 52-week low, investors may pay increased attention to see if there will be a move through that level. Scanning back over the past 12 weeks, the stock has moved -22.34%. Heading back to the beginning of the calendar year, we can see that shares have changed -38.36%. Over the last 4 weeks, shares have seen a change of -10.1%. Over the last 5 sessions, the stock has moved -6.58%.
Making money in the stock market can be challenging, but it is not impossible. Accomplished investors typically have a well-rounded understanding of how markets function. Many successful investors have learned to be patient, disciplined, and ready to jump on any opportunity that arises. Securing higher returns on investment dollars may take some extra time and effort for those who do not have a lengthy background in the stock market. Although there are many types of investments out there, investing in stocks has traditionally provided the highest potential for returns. To realize consistent returns, investors typically have to maintain a steadfast approach and be willing to adapt to changing market environments over time.
Sell-side analysts have the capability of providing stock ratings for companies that they cover. According to analysts polled by Zacks Research, the current average broker rating on shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) is 1.57. This average rating includes analysts who have offered Sell, Buy and Hold ratings on the stock. This rating falls on a numeric scale from 1 to 5. A score of 1 would indicate a Buy recommendation, and a score of 5 would represent a Sell recommendation. Out of all the analysts offering ratings, 11 have pegged the stock a Strong Buy or Buy, based on data provided by Zacks Research.
Tracking the current quarter consensus EPS estimate for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), we have noted that the number is currently -1.39. This estimate is using 8 contributing analysts polled by Zacks Research. For the last quarter, the company posted a quarterly EPS of -2.03. Sell-side Wall Street analysts study companies and provide their opinions of where the stock might be going in the future. A lot of weight is given to analyst estimates, and earnings beats or misses revolve around these predictions. Sometimes these estimates are very close to the actual, and other times they are not. When a company announces actual earnings results, a large surprise factor can result in increased volatility. If a company beats estimates and posts a positive earnings surprise, the stock may see a near-term bump in price. On the flip side, a negative surprise may move the stock lower. Based on the unknown, many investors may choose to trade with caution around earnings releases.
Analysts have set a target price on shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE). The current consensus price target is $159.64. Wall Street analysts often provide price target projections on stocks that they cover. Price target projections can be created using a wide variety of methods. Many investors will closely track stock target prices, especially when analysts make updates. A thorough research report will generally offer detailed reasoning for a certain target projection. Some investors may watch sell-side targets very closely and use the information to help with their own stock research.